Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 18 years of age or older at the time of signing the consent form.
- People who have multiple myeloma (MM) that has come back after previous treatment, as defined by international medical guidelines.
- People whose myeloma can be measured through specific blood, urine, or protein tests that show the disease is active at a detectable level.
- People who are well enough to carry out basic daily activities, with a general health score of 0, 1, or 2 on a standard medical scale (ranging from fully active to capable of self-care but unable to work).
- People who have previously been treated with at least two of the following types of myeloma therapy: a proteasome inhibitor, an IMiD (a type of immune-modifying drug), or an anti-CD38 antibody.
- People whose myeloma got worse during or after their most recent myeloma treatment.
- People who have a capable caregiver available to supervise them when taking the study medication at home.
- People whose blood test results meet minimum levels for white blood cells and platelets, as confirmed by the trial site.
- Women of childbearing potential who have a negative pregnancy test at the start of the study, and who (along with fertile male participants who are sexually active with someone who could become pregnant) agree to use highly effective contraception throughout the study and for 3 months after the last dose.
Who may not be able to join:
- People with a significant medical condition, abnormal laboratory results, or a psychiatric illness that would prevent safe participation in the study.
- People who have previously experienced a condition called ICANS (immune effector cell-associated neurotoxicity syndrome), which is a type of neurological side effect from certain cancer treatments (confirm with trial site).
- People who have had another type of cancer in the past, unless they have been cancer-free for 5 or more years — though some minor skin cancers, early-stage cervical or breast changes, or certain early-stage prostate cancers may be exceptions (confirm with trial site).
- People who have plasma cell leukaemia, Waldenström's macroglobulinaemia, POEMS syndrome, or a condition called clinically significant amyloidosis.
- Women who are pregnant, breastfeeding, or who plan to become pregnant during the study.
- People who have HIV, active or chronic hepatitis B, or active hepatitis A or C.
- People who live on an island with no bridge or direct road connection to the mainland.
- People who are unable to record their health and symptom information electronically as required by the study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Thomas Lund, MD, Odense Universitetshospital
Phone: +45 29648494
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluate the safety of self-administration of Elranatamab in the patients' own homes assessed by checklist
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.